@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:11892; a Protein: . sub:_2 geneProductOf: hgnc:6840; a Protein: . sub:_3 occursIn: species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:TNF) -> p(HGNC:MAP2K1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "TNF alpha, IFN gamma and IL1 beta induced the tyrosine and threonine phosphorylation of ERK MAP kinases. Treatment with PD98059, an inhibitor of MEK1 and MEK2 kinase inhibited ERK MAP kinase phosphorylation by IFN gamma, TNF alpha and IL1 beta."; prov:wasQuotedFrom pubmed:10873157 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:10873157; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:51.468+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }